Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Nonalcoholic steatohepatitis (NASH) is a condition which can progress to cirrhosis and hepatocellular carcinoma. Markers for NASH diagnosis are still lacking. We performed a comprehensive lipidomic analysis on human liver biopsies including normal liver, nonalcoholic fatty liver and NASH. Random forests-based machine learning approach allowed characterizing a signature of 32 lipids discriminating NASH with 100% sensitivity and specificity. Furthermore, we validated this signature in an independent group of NASH patients. Then, metabolism dysregulations were investigated in both patients and murine models. Alterations of elongase and desaturase activities were observed along the fatty acid synthesis pathway. The decreased activity of the desaturase FADS1 appeared as a bottleneck, leading upstream to an accumulation of fatty acids and downstream to a deficiency of long-chain fatty acids resulting to impaired phospholipid synthesis. In NASH, mass spectrometry imaging on tissue section revealed the spreading into the hepatic parenchyma of selectively accumulated fatty acids. Such lipids constituted a highly toxic mixture to human hepatocytes. In conclusion, this study characterized a specific and sensitive lipid signature of NASH and positioned FADS1 as a significant player in accumulating toxic lipids during NASH progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These data were confirmed by Chiappini et al.,98 who showed a significant reduction in PC, PE and SM in MASH.”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 4×
“defined by the presence of steatosis, ballooning of hepatocytes, Mallory’s bodies and lobular inflammation with infiltrated macrophages and leukocytes on liver histology 8,9 .”
InfluentialMembrane lipids: where they are and how they behave
van Meer, G., Voelker, D. R., & Feigenson, G. W. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2330 · Cited by 7,157
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Random Forest: A Classification and Regression Tool for Compound Classification and QSAR Modeling
Svetnik, V., Liaw, A., Tong, C., Culberson, J. C., Sheridan, R. P., & Feuston, B. P. (2003) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci034160g · Cited by 3,573
Byrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,042
Cited by
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
Geng, Y., Faber, K. N., de Meijer, V. E., Blokzijl, H., & Moshage, H. (2021) · Hepatology International · doi:10.1007/s12072-020-10121-2 · Cited by 432
Azzu, V., Vacca, M., Virtue, S., Allison, M., & Vidal-Puig, A. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.054 · Cited by 369
Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.06.031 · Cited by 332
Physiological and pathological roles of lipogenesis
Jeon, Y. G., Kim, Y. Y., Lee, G., & Kim, J. B. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00786-y · Cited by 243
Metadata
- Authors
- Chiappini, F., Coilly, A., Kadar, H., Gual, P., Tran, A., Desterke, C., Samuel, D., Duclos-Vallée, J.-C., Touboul, D., Bertrand-Michel, J., Brunelle, A., Guettier, C., & Le Naour, F.
- Affiliations
- Université Paris-Sud (FR)
- Inserm (FR)
- Corresponding author
- Chiappini, Franck
- ORCID
- Venue
- Scientific Reports
- Published
- 2017-04-24
- Volume
- 7
- Issue
- 1
- Pages
- 46658-46658
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5402394
- OpenAlex
- W2609371482
- Cited by
- 246
- References
- 71
- Citations by year
- 2026: 16 · 2025: 31 · 2024: 35 · 2023: 37 · 2022: 27 · 2021: 36 · 2020: 28 · 2019: 19 · 2018: 14 · 2017: 2
- FWCI
- 13.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- HAL (submittedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-11-INBS, ANR-10, ANR-10-LABX, ANR-10-LABX-0033, ANR-11-INBS-0010)
- Institut National de la Santé et de la Recherche Médicale
- Fondation pour la Recherche Médicale (SPF20111223621)
- Centre National de la Recherche Scientifique (ANR-11-INBS-0010)
- Centre Hospitalier Universitaire de Nice
- Université Paris-Sud
- Laboratoire d'Excellence en Recherche sur le Médicament et l'Innovation Thérapeutique
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- nonalcoholic steatohepatitis, lipidomics, lipid signatures, FADS1, fatty acid desaturase, fatty acid synthesis, fatty acid accumulation, phospholipid synthesis, hepatocyte cytotoxicity, non-alcoholic fatty liver disease, liver biopsy, mass spectrometry imaging, metabolic dysfunction, NASH diagnosis
- MeSH terms
- Fatty Acid Elongases, Delta-5 Fatty Acid Desaturase, Acetyltransferases, Adult, Animals, Cells, Cultured, Fatty Acids, Female, Carcinoma, Hepatocellular, Humans, Lipids, Liver Cirrhosis, Liver Neoplasms, Male, Mice, Inbred C57BL, Middle Aged, Disease Progression, Hepatocytes, Fatty Acid Desaturases, Lipid Metabolism, Metabolomics, Hep G2 Cells, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.